Form 4: Structure Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Xichen Lin, CHIEF SCIENTIFIC OFFICER of Structure Therapeutics Inc., sold 3,939 shares of common stock on August 4, 2026.
Summary
- Option exercise/conversion: acquired 11,817 Ordinary Shares at $0.34 ($4,018) on August 4, 2026; holds 240,777 after (Direct).
- Conversion of derivative: disposed of 11,817 Ordinary Shares on August 4, 2026; holds 228,960 after (Direct).
- Option exercise/conversion: disposed of 11,817 Share Option (right to buy) on August 4, 2026; holds 154,715 after (Direct).
- Conversion of derivative: acquired 3,939 American Depositary Shares on August 4, 2026; holds 3,939 after (Direct).
- Open-market sale: disposed of 3,100 American Depositary Shares at $49.29 ($152,786) on August 4, 2026; holds 839 after (Direct).
- Open-market sale: disposed of 839 American Depositary Shares at $50.03 ($41,974) on August 4, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $194,760 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Xichen Lin — Officer (CHIEF SCIENTIFIC OFFICER)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-04 | Option exercise/conversion | Ordinary Shares | 11,817 | $0 | $4.0K | 240,777 |
| 2026-08-04 | Conversion of derivative | Ordinary Shares | 11,817 | — | — | 228,960 |
| 2026-08-04 | Option exercise/conversion | Share Option (right to buy) | 11,817 | — | — | 154,715 |
| 2026-08-04 | Conversion of derivative | American Depositary Shares | 3,939 | — | — | 3,939 |
| 2026-08-04 | Open-market sale | American Depositary Shares | 3,100 | $49 | $152.8K | 839 |
| 2026-08-04 | Open-market sale | American Depositary Shares | 839 | $50 | $42.0K | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-04 | Option exercise/conversion (11,817 shares) |
| 2026-08-04 | Conversion of derivative (11,817 shares) |
| 2026-08-04 | Option exercise/conversion (11,817 shares) |
| 2026-08-04 | Conversion of derivative (3,939 shares) |
| 2026-08-04 | Open-market sale (3,100 shares) |
| 2026-08-04 | Open-market sale (839 shares) |
Keywords
insider transaction, Form 4, GPCR, Structure Therapeutics Inc., bearish, Xichen Lin
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.